Ring Nitrogen Of The Seven-membered Hetero Ring Is Shared By An Additional Cyclo Of The Polycyclo Ring System Patents (Class 514/214.01)
-
Publication number: 20110311480Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: August 31, 2011Publication date: December 22, 2011Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
-
Publication number: 20110293676Abstract: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.Type: ApplicationFiled: August 11, 2011Publication date: December 1, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventors: Dennis BROWN, Shawnya MICHAELS
-
Patent number: 8039460Abstract: Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: October 12, 2005Date of Patent: October 18, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Daniel V. Paone, Anthony W. Shaw, Diem N. Nguyen, Zhengwu J. Deng, Theresa M. Williams, Joseph P. Vacca, Craig M. Potteiger, Harold G. Selnick
-
Publication number: 20110237567Abstract: This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.Type: ApplicationFiled: October 12, 2007Publication date: September 29, 2011Applicant: XENON PHARMACEUTICALS INC.Inventors: Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Ranjender Kamboj
-
Publication number: 20110124630Abstract: An objective of the invention is to provide a compound effective for prevention and/or treatment of cancer. The invention relates to a compound according to by formula I, or a salt, solvate or physiologically functional derivative thereof, and a composition for prevention and/or treatment of cancer comprising the same as an active ingredient: wherein R1 to R6, x, and y are as defined in the description.Type: ApplicationFiled: December 18, 2008Publication date: May 26, 2011Inventors: Naofumi Mukaida, Hiroyuki Ishibashi, Tsuyoshi Taniguchi
-
Publication number: 20110092486Abstract: The present invention relates to use of an Ih channel inhibitor for the manufacture of a medicament for the promotion of wakefulness in a subject in need thereof, in particular, wherein the subject is suffering from excessive sleepiness which may result from a sleep disorder.Type: ApplicationFiled: October 18, 2007Publication date: April 21, 2011Inventors: Nicholas Matthew Ward, Gerardus Stephanus Francisc Ruigt, Hugh Marston
-
Publication number: 20110020277Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: March 26, 2009Publication date: January 27, 2011Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: John A. Bender, Zhong Yang, John F. Kadow
-
Publication number: 20110020275Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: March 25, 2009Publication date: January 27, 2011Inventors: Kap-Sun Yeung, Ying Han, John F. Kadow
-
Publication number: 20110009388Abstract: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.Type: ApplicationFiled: February 2, 2010Publication date: January 13, 2011Inventor: Dennis M. BROWN
-
Publication number: 20110008307Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.Type: ApplicationFiled: April 15, 2010Publication date: January 13, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. BROWN
-
Patent number: 7867998Abstract: Method for relieving cough using an effective antitussive chemical compound belonging to stemoamide or tuberostemospironine and method for manufacturing pharmaceutical compositions for treating or relieving cough in human and animal subjects which including a stemoamide or tuberostemospironine compound. In addition, the antitussive property of the compounds provides a method for assessing the quality of herbs traditionally used in treating cough by analyzing the content of the effective chemical ingredient, i.e., compounds of stemoamide type and/or tuterostemospironine type. It further provides a method for identifying medicinal herbs which may be used for relieving cough by phytochemical determination of the existence of compounds that are of stemoamide or tuterostemospironine type.Type: GrantFiled: September 12, 2005Date of Patent: January 11, 2011Assignee: Hong Kong Jockey Club Institute of Chinese Medicine LimitedInventors: Pui-Hay Paul But, Yan-Tong Xu, Pang Chui Shaw, Ren Wang Jiang, Po Ming Hon
-
Patent number: 7858114Abstract: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.Type: GrantFiled: May 7, 2007Date of Patent: December 28, 2010Assignee: Teikoku Seiyaku Co., Ltd.Inventor: Takeshi Ito
-
Patent number: 7842687Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.Type: GrantFiled: May 25, 2006Date of Patent: November 30, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventors: Jean-Pierre Robin, Julie Blanchard, Jean-Pierre Marie, Nina Radosevic
-
Patent number: 7790712Abstract: The application relates to compounds of formula Ia and analogues thereof wherein R1 to R13 and X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.Type: GrantFiled: March 17, 2006Date of Patent: September 7, 2010Assignee: Boehringer Ingelheim Pharmaceutical, Inc.Inventors: Derek Cogan, Donghong A. Gao, Daniel R. Goldberg, Craig Andrew Miller, Neil Moss, Matthew Russell Netherton, Philip Dean Ramsden, Zhaoming Xiong
-
Publication number: 20100221221Abstract: This disclosure relates to novel N-phenyl-2-pyrimidineamines and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering protein-tyrosine kinase inhibitors.Type: ApplicationFiled: August 11, 2009Publication date: September 2, 2010Applicant: CONCERT PHARMACEUTICALS INC.Inventors: Scott L. Harbeson, Julie F. Liu, Roger Tung
-
Publication number: 20100216774Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: February 23, 2010Publication date: August 26, 2010Inventors: John A. Bender, Kyle Eastman, John F. Kadow, Zhong Yang
-
Publication number: 20100216773Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.Type: ApplicationFiled: February 11, 2010Publication date: August 26, 2010Applicant: National Health Research InstitutesInventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee
-
Publication number: 20100160291Abstract: This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.Type: ApplicationFiled: October 12, 2007Publication date: June 24, 2010Applicant: XENON PHARMACEUTICALS INC.Inventors: Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Ranjender Kamboj
-
Patent number: 7696374Abstract: The invention relates to a compound having general formula (I): Wherein n, A, R1, R2, and R3 are as defined herein. The invention also relates to methods of preparation of compound of formula (I) as well as its use in therapeutics.Type: GrantFiled: March 31, 2006Date of Patent: April 13, 2010Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Antonio Almario Garcia
-
Patent number: 7683050Abstract: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.Type: GrantFiled: August 1, 2006Date of Patent: March 23, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Patent number: 7662809Abstract: The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, R14, R15, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.Type: GrantFiled: October 25, 2005Date of Patent: February 16, 2010Assignee: Istituto di Richerche di Biologia Molecolare P Angeletti SpAInventors: Caterina Ercolani, Joerg Habermann, Frank Narjes, Simona Ponzi, Michael Rowley, Ian Stansfield
-
Publication number: 20100029616Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters and prodrugs thereof, pharmaceutical compositions containing compounds of formula (I) and the use of said compounds and compositions as urotensin II receptor antagonists.Type: ApplicationFiled: July 31, 2009Publication date: February 4, 2010Inventors: William A. Kinney, Diane K. Luci, Bruce E. Maryanoff, Shyamali Ghosh, Edward C. Lawson
-
Patent number: 7652004Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: July 28, 2008Date of Patent: January 26, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Scott W. Martin, Carl P. Bergstrom, Robert G. Gentles, Kap-Sun Yeung
-
Publication number: 20100009959Abstract: The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.Type: ApplicationFiled: May 4, 2007Publication date: January 14, 2010Applicant: Instituto di Ricerche di Biologia Molecolare P. Angeletti SPAInventors: Elena Capito, Joerg Habermann, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
-
Patent number: 7642251Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: August 1, 2008Date of Patent: January 5, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Carl P. Bergstrom, Scott W. Martin
-
Publication number: 20090280083Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: May 4, 2009Publication date: November 12, 2009Inventors: Scott W. Martin, Carl P. Bergstrom, Min Ding, Xiaofan Zheng, Robert G. Gentles
-
Publication number: 20090275561Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: February 11, 2009Publication date: November 5, 2009Inventors: Scott W. Martin, Carl P. Bergstrom, Robert G. Gentles, Kap-Sun Yeung
-
Publication number: 20090270368Abstract: The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. BROWN
-
Publication number: 20090176759Abstract: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.Type: ApplicationFiled: December 8, 2008Publication date: July 9, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis Brown
-
Publication number: 20090162318Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: February 25, 2009Publication date: June 25, 2009Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
-
Publication number: 20090156560Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 18, 2009Inventors: JOSE LUIS MILLAN, EDUARD SERGIENKO
-
Patent number: 7547690Abstract: The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: February 28, 2008Date of Patent: June 16, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert G. Gentles, Xiaofan Zheng, Min Ding, Yong Tu, Ying Han, Piyasena Hewawasam, John F. Kadow, John A. Bender, Kap-Sun Yeung, Katharine A. Grant-Young, Thomas W. Hudyma
-
Publication number: 20090149445Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.Type: ApplicationFiled: July 15, 2008Publication date: June 11, 2009Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
-
Patent number: 7541351Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: January 9, 2008Date of Patent: June 2, 2009Assignee: Bristol-Myers Squibb CompanyInventors: John A. Bender, Min Ding, Robert G. Gentles
-
Patent number: 7541352Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: January 30, 2008Date of Patent: June 2, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, John F. Kadow, Katharine A. Grant-Young
-
Patent number: 7541353Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: March 11, 2008Date of Patent: June 2, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert G. Gentles, Xiaofan Zheng, Min Ding, Yong Tu, Ying Han, Piyasena Hewawasam, John F. Kadow, John A. Bender, Kap-Sun Yeung, Katharine A. Grant-Young, Thomas W. Hudyma
-
Patent number: 7538103Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: March 11, 2008Date of Patent: May 26, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Piyasena Hewawasam, Yong Tu
-
Patent number: 7538102Abstract: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: March 11, 2008Date of Patent: May 26, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, John A. Bender, Robert G. Gentles, Zhong Yang, Min Ding, Yong Tu, Piyasena Hewawasam, Ying Han, John F. Kadow
-
Publication number: 20090130057Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: November 18, 2008Publication date: May 21, 2009Inventors: Piyasena Hewawasam, Yong Tu, John A. Bender, Zhong Yang
-
Patent number: 7521443Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: November 19, 2007Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
-
Patent number: 7521442Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: May 23, 2007Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert G. Gentles, Min Ding, Piyasena Hewawasam
-
Patent number: 7521444Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: March 11, 2008Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: John A. Bender, Robert G. Gentles, Ying Han, Yong Tu, Zhong Yang, Kap-Sun Yeung, Katharine A. Grant-Young
-
Patent number: 7521441Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: May 7, 2007Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert G. Gentles, Piyasena Hewawasam, Min Ding, Carl P. Bergstrom, Scott W. Martin, Kap-Sun Yeung, Thomas W. Hudyma, Xiaofan Zheng, John A. Bender, John F. Kadow
-
Patent number: 7517872Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: February 15, 2008Date of Patent: April 14, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Andrew Nickel, John F. Kadow
-
Publication number: 20090074715Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: July 28, 2008Publication date: March 19, 2009Inventors: Scott W. Martin, Carl P. Bergstrom, Robert G. Gentles, Kap-Sun Yeung
-
Publication number: 20090068236Abstract: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.Type: ApplicationFiled: April 14, 2008Publication date: March 12, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventors: Dennis Brown, Shawnya Michaels
-
Publication number: 20090069294Abstract: The present disclosure relates to XIAP inhibitor compounds of the formula I.Type: ApplicationFiled: June 6, 2006Publication date: March 12, 2009Inventors: Zhuoliang Chen, Mark G. Palermo, Sushil K. Sharma, Troy Smith, Christopher S. Straub, Run-Ming D. Wang, Yaping Wang, Leigh Zawel
-
Patent number: 7485633Abstract: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: March 12, 2007Date of Patent: February 3, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Nicholas A. Meanwell, Robert G. Gentles, Min Ding, John A. Bender, John F. Kadow, Piyasena Hewawasam, Thomas W. Hudyma, Xiaofan Zheng
-
Patent number: 7473688Abstract: The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: GrantFiled: September 6, 2006Date of Patent: January 6, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Carl P. Bergstrom, John A. Bender, Robert G. Gentles, Piyasena Hewawasam, Thomas W. Hudyma, John F. Kadow, Scott W. Martin, Alicia Regueiro-Ren, Kap-Sun Yeung, Yong Tu, Katharine A. Grant-Young, Xiaofan Zheng
-
Publication number: 20090005357Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: ApplicationFiled: September 11, 2008Publication date: January 1, 2009Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Miodrag Radulovacki, David W. Carley